Apnimed, Inc. is a late-stage clinical pharmaceutical company focused on the discovery, development, and commercialization of novel oral therapies for sleep-related breathing diseases. The company's primary business activity centers on addressing the neurobiology of obstructive sleep apnea (OSA). Its sole clinical product candidate, AD109, is an oral therapeutic designed to treat an underlying cause of OSA. Apnimed targets the OSA community with the goal of simplifying intervention and expanding the reach of diagnosis and treatment through safe and effective oral medications.

Summarised from the company's own disclosures, fiscal year ended Oct 2026

Industry Biotechnology Homepage ir.apnimed.com
Sector Healthcare IR page ir.apnimed.com
Tags
obstructive sleep apnea, oral therapies, sleep-related breathing diseases, neurobiology, clinical-stage, AD109
Press page —

Metrics

Valuation  
Market cap —
Market cap (USD) —
P/E —
PEG —
P/BV —
P/S —
P/OCF —
P/FCF —
Dividend yield —
Turnover / mcap —
Returns  
ROE —
ROI —
ROIC —
Profit margin —
Growth  
Revenue growing —
Profits growing —
Revenue up 3y —
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable —
Margin expanding —
Buying back stock —
Diluting (TTM) —
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 9
Quality score —
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure Q3 2026 Q2 2026
Revenue 2.48M 12.08M
Net profit -29.524M 125.935M

Figure Q3 2026 Q2 2026
Share price 21.91 —
P/OCF -10.77 —

Filed figures

Figure Dec 2025
Balance sheet detail
Trade receivables (USD) 959,000
Borrowings, non-current (USD) 0.00
Lease liabilities (USD) 873,000
Cash and deposits (USD) 41.9M
Right-of-use assets (USD) 835,000
Net debt (borrowings + leases - cash) (USD) -41M
Reported Sep 8, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

•New Drug Application (“NDA”) for AD109, with a proposed proprietary name Oxnimbi™ (aroxybutynin and atomoxetine) tablets, for oral use, remains under U.S. Food and Drug Administration (“FDA”) review with a February 28, 2027, Prescription Drug User Fee Act (“PDUFA”) goal date

•Commercial readiness activities advance in preparation for a potential U.S. launch

•Presented five abstracts at CHEST 2026, including two late-breakers, highlighting AD109 Phase 3 clinical data and the burden of OSA

•$351.8 million in cash and cash equivalents as of September 30, 2026, expected to fund the potential U.S. launch of Oxnimbi and operations into the second quarter of 2028

CAMBRIDGE, Mass., November 16, 2026– Apnimed, Inc. (Nasdaq: APMD) (“Apnimed”), a late-stage clinical pharmaceutical company dedicated to the discovery, development and commercialization of novel oral therapies that address the neurobiology of sleep-related breathing diseases, today announced its financial results for the third quarter ended September 30, 2026, and provided a corporate update.

“We are in a transformational period at Apnimed,” said Kevin Lind, Chief Executive Officer of Apnimed.

Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review

On November 13, 2026, the Audit Committee of the Board of Directors (the “Audit Committee”) of Apnimed, Inc. (the “Company”), based on the recommendation of the Company’s management, concluded that the Company’s previously issued financial statements, as described below, should no longer be relied upon due to an error identified in the classification of the gain on the disposition of the Company’s equity method investment in Shionogi-Apnimed Sleep Science, LLC (“SASS”) for the three and six months ended June 30, 2026 as a gain in continuing operations rather than discontinued operations. The correction of such classification for such periods does not have any impact on revenue - related party, income (loss) from operations, total net income (loss), total net income (loss) per share, cash, total assets, total liabilities or stockholders' equity (deficit), or net cash flows from operating, investing and financing activities as previously reported in the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2026.

October 12, 2026

CHEST-led panel to showcase data from the Phase 3 SynAIRgy and LunAIRo trials, exploring potential new paradigms for advancing OSA patient management

CAMBRIDGE, Mass., Oct. 12, 2026 (GLOBE NEWSWIRE) -- Apnimed, Inc. (Nasdaq: APMD) ("Apnimed"), a late stage clinical pharmaceutical company dedicated to the discovery, development and commercialization of novel oral therapies that address the neurobiology of sleep-related breathing diseases, today announced that five abstracts have been accepted for presentation at the American College of Chest Physicians' CHEST 2026 Annual Meeting, taking place October 18–21 in Phoenix, Ariz. Three abstracts feature data from the Phase 3 program evaluating the investigational drug AD109 (aroxybutynin 2.3 mg/atomoxetine 75 mg) in obstructive sleep apnea (OSA), including two late-breaking abstracts that will be presented as a rapid-fire oral presentation and a poster. The other two abstracts present real-world data on the burden of OSA. CHEST will also host a panel discussion on the results of the Phase 3 SynAIRgy and LunAIRo trials and their potential application to OSA management.

CHEST 2026 Annual Meeting Presentation Details:

Late-Breaking – Rapid Fire Oral Presentation

Title: Aroxybutynin and Atomoxetine (AD109) in Post-menopausal Women with Obstructive Sleep Apnea

Session: Top Late-Breaking Abstracts: New Trial Data from Bench to Bronchoscope

Session Date, Time: Oct 20th, 2:15-2:19 PM

Location: Phoenix Convention Center Exhibit Hall Rapid Fire Area 4D

Late-Breaking Poster Presentation

Title: Baseline Hypoxic Burden as a Potential Marker of Blood Pressure Response to AD109 in Obstructive Sleep Apnea

Poster #: 3217

Session: Late-Breaking Scientific Abstract Posters (B): Pulmonary Vascular Disease, Sleep Disorders

Session Date, Time: Oct 20th, 1:45 – 2:30 PM

Location: Phoenix Convention Center Exhibit Hall Poster Area 2

Poster Presentations

Title: OSA Negatively Impacts Quality of Life, Work Productivity, and Daily Activities: Findings From a Real-world Study in the United States

Poster #: 3193

Session: Sleep Scientific Abstract Posters (F): Respiratory-related sleep disorders

Session Date, Time: Oct 20th, 1:45 – 2:30 PM

Location: Phoenix Convention Center Exhibit Hall Poster Area 2

Title: Patient And Physician Agreement on Symptoms of OSA at Diagnosis: A Real-world Study in the United States

Poster #: 3194

Session: Sleep Scientific Abstract Posters (F): Respiratory-related sleep disorders

Session Date, Time: Oct 20th, 1:45 – 2:30 PM

Location: Phoenix Convention Center Exhibit Hall Poster Area 2

Title: A Per-protocol Analysis of Patient-reported Outcomes in the Phase 3 Clinical Trials of Aroxybutynin and Atomoxetine (AD109) in Obstructive Sleep Apnea

Poster #: 3196

Session: Sleep Scientific Abstract Posters (F): Respiratory-related sleep disorders

Session Date, Time: Oct 20th, 1:45 – 2:30 PM

Location: Phoenix Convention Center Exhibit Hall Poster Area 2

CHEST Panel Discussion

Title: New Medications for Treatment of OSA: The SynAIRgy and LunAIRo Trials

Date, Time: Oct. 20th, 9:15–10:15 a.m. MST

Location: Phoenix Convention Center, North Building, Room 127 B

Chair: Patrick Strollo, MD, MS, FCCP

Co-Chair: Kara Dupuy-McCauley, MD, FCCP

Description: The panel will discuss the results of the SynAIRgy and LunAIRo trials, their potential application to OSA management and considerations beyond AHI when evaluating treatment options.

Apnimed-Sponsored Learning Theater

Title: Clinical Overview of an Investigational Oral Tablet for OSA

Date, Time: Oct 21st, 12:30 – 1:15 PM

Location: Phoenix Convention Center Exhibit Hall Learning Theater 3

**Speakers:**Amir Sharafkhaneh, MD, PhD, and Dennis Hwang, MD

Description: Through an interactive format using clinical profiles, faculty will explore the heterogeneity of obstructive sleep apnea and the importance of multidimensional assessment beyond AHI. The faculty panel will discuss and present emerging clinical evidence from an investigational oral tablet, AD109, in the context of evolving OSA research.​

Prompts

Apnimed, Inc. (ticker APMD), listed in United States.

ETFs Holding Apnimed, Inc.

ETF Weight in ETF Shares Market value As of
JDOC 0.23% 1,276 $ 22.713K Nov 17, 2026